ArriVent: Fumatinib Phase III trial did not meet primary endpoint.

Allist announced that the FURVENT Phase III trial of its product furmonertinib as monotherapy for first-line treatment of EGFR exon 20 insertion-mutated NSCLC did not meet the primary endpoint, namely PFS assessed by BICR. Clinical benefit was observed in secondary endpoints including investigator-assessed PFS and BICR-assessed ORR. Although OS data are not yet mature, an improving trend has been observed. The safety profile was consistent with previous studies, with no new signals identified. The company is evaluating the full dataset with ArriVent to determine next steps. As of September 30, 2026, cumulative investment in this clinical trial amounted to approximately RMB 70.82 million, which has been recognized in current profit or loss and will not have a material impact on current-period performance.